Page last updated: 2024-09-03

tazobactam and Neoplasms

tazobactam has been researched along with Neoplasms in 14 studies

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (7.14)18.2507
2000's8 (57.14)29.6817
2010's4 (28.57)24.3611
2020's1 (7.14)2.80

Authors

AuthorsStudies
Charoenkwan, P; Choeyprasert, W; Fanhchaksai, K; Kamonrattana, R; Natesirinilkul, R; Sathitsamitphong, L1
Adams, R; Agus, A; Barnes, RA; Chau, I; Clarke, M; Coyle, V; Doran, A; Forde, C; Grayson, M; McAuley, DF; McDowell, C; McMullan, R; Plummer, R; Thomas, AL; Wilson, RH1
Akova, M; Albasanz-Puig, A; Araos, R; Bote, A; Brunel, AS; Calik, S; Carratalà, J; Del Pozo, JL; Drgona, L; García, E; Gomes, MZR; Gudiol, C; Hemmati, P; Herrera, F; Ibrahim, KY; Isler, B; Kanj, S; Kern, W; Maestro de la Calle, G; Manzur, A; Marin, JI; Márquez-Gómez, I; Martín-Dávila, P; Mikulska, M; Montejo, JM; Montero, M; Morales, HMP; Morales, I; Novo, A; Oltolini, C; Parody, R; Peghin, M; Puerta-Alcalde, P; Ruiz-Camps, I; Sipahi, OR; Tebe, C; Tilley, R; Yáñez, L1
Brock, B; Friberg, LE; Kristoffersson, AN; Maarbjerg, SF; Nielsen, EI; Schrøder, H; Thorsted, A; Wang, M1
Cho, SY; Chung, DR; Ha, YE; Jung, CW; Kang, CI; Kang, ES; Ko, JH; Lee, JY; Lee, WJ; Peck, KR; Song, JH1
Glasmacher, A; Wade, JC1
Bethe, U; Breuer, K; Cornely, OA; Diehl, V; Fätkenheuer, G; Karthaus, M; Reichert, D; Salzberger, B; Schwonzen, M; Seifert, H; Ullmann, AJ; Wicke, T1
Aksoylar, S; Cetingül, N; Kansoy, S; Kantar, M; Karapinar, D; Kavakli, K1
Bermúdez, A; Besalduch, J; Nocea, G; Pascual, MJ; Rovira, M; Sanz, MA; Sanz-Rodríguez, C1
Bellaire, T; Cornely, OA; Dörken, B; Einsele, H; Krause, S; Kubin, T; Maschmeyer, G; Reich, G; Sandherr, M; Thiel, E1
Böhme, C; Hess, U; Rey, K; Senn, HJ1
Bradley, SJ1
Abi-Said, D; Bivins, C; Hachem, R; Hanna, H; Huaringa, A; Raad, I; Sukumaran, A; Thornby, J; Walsh, G; Whimbey, E1
Bode, U; Fleischhack, G; Hasan, C; Havers, W; Marklein, G; Schmidt-Niemann, M; Wulff, B1

Trials

10 trial(s) available for tazobactam and Neoplasms

ArticleYear
A Randomized, Open-Labeled, Prospective Controlled Study to Assess the Efficacy of Frontline Empirical Intravenous Piperacillin/Tazobactam Monotherapy in Comparison with Ceftazidime Plus Amikacin for Febrile Neutropenia in Pediatric Oncology Patients.
    Asian Pacific journal of cancer prevention : APJCP, 2019, 09-01, Volume: 20, Issue:9

    Topics: Administration, Intravenous; Amikacin; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Ceftazidime; Child; Child, Preschool; Drug Therapy, Combination; Febrile Neutropenia; Female; Follow-Up Studies; Humans; Male; Neoplasms; Piperacillin; Prospective Studies; Retrospective Studies; Tazobactam; Treatment Outcome

2019
Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis (the EASI-SWITCH trial): study protocol for a randomised controlled trial.
    Trials, 2020, May-27, Volume: 21, Issue:1

    Topics: Administration, Intravenous; Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ciprofloxacin; Cost-Benefit Analysis; Drug Administration Schedule; Equivalence Trials as Topic; Humans; Meropenem; Multicenter Studies as Topic; Neoplasms; Neutropenia; Piperacillin; Pragmatic Clinical Trials as Topic; Quality of Life; Sepsis; Tazobactam; Treatment Outcome

2020
Vancomycin does not benefit persistently febrile neutropenic people with cancer.
    Cancer treatment reviews, 2004, Volume: 30, Issue:1

    Topics: Anti-Bacterial Agents; Double-Blind Method; Drug Therapy, Combination; Evidence-Based Medicine; Female; Fever; Follow-Up Studies; Humans; Male; Neoplasms; Neutropenia; Penicillanic Acid; Piperacillin; Probability; Proportional Hazards Models; Reference Values; Risk Assessment; Severity of Illness Index; Tazobactam; Treatment Outcome; Vancomycin

2004
Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia.
    International journal of hematology, 2004, Volume: 79, Issue:1

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Bacterial Infections; Disease Susceptibility; Drug Administration Schedule; Drug Therapy, Combination; Female; Fever; Fever of Unknown Origin; Humans; Immunocompromised Host; Levofloxacin; Male; Middle Aged; Neoplasms; Neutropenia; Ofloxacin; Penicillanic Acid; Piperacillin; Prospective Studies; Safety; Tazobactam; Treatment Outcome

2004
Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children.
    Pediatric hematology and oncology, 2004, Volume: 21, Issue:2

    Topics: Amikacin; Anti-Bacterial Agents; Drug Therapy, Combination; Fever; Fungi; Gram-Negative Bacteria; Gram-Positive Bacteria; Hematologic Neoplasms; Humans; Infections; Meropenem; Neoplasms; Netilmicin; Neutropenia; Penicillanic Acid; Piperacillin; Tazobactam; Thienamycins

2004
Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study.
    Current medical research and opinion, 2005, Volume: 21, Issue:5

    Topics: Adult; Amikacin; Anti-Bacterial Agents; Cilastatin; Cost-Benefit Analysis; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fever; Hematopoietic Stem Cell Transplantation; Humans; Imipenem; Male; Middle Aged; Neoplasms; Neutropenia; Penicillanic Acid; Piperacillin; Prospective Studies; Protease Inhibitors; Spain; Tazobactam; Treatment Outcome

2005
Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial.
    British journal of haematology, 2005, Volume: 130, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Female; Fever; Hematopoietic Stem Cell Transplantation; Humans; Male; Meropenem; Middle Aged; Neoplasms; Neutropenia; Opportunistic Infections; Penicillanic Acid; Piperacillin; Prospective Studies; Tazobactam; Thienamycins

2005
Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 1998, Volume: 6, Issue:4

    Topics: Adolescent; Adult; Aged; Amikacin; Analysis of Variance; Anti-Bacterial Agents; Ceftazidime; Chi-Square Distribution; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fever; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Penicillanic Acid; Piperacillin; Prognosis; Prospective Studies; Tazobactam; Treatment Failure; Treatment Outcome

1998
Treatment of nosocomial postoperative pneumonia in cancer patients: a prospective randomized study.
    Annals of surgical oncology, 2001, Volume: 8, Issue:2

    Topics: Aged; Amikacin; Aztreonam; Chi-Square Distribution; Clindamycin; Cross Infection; Drug Therapy, Combination; Humans; Middle Aged; Neoplasms; Opportunistic Infections; Penicillanic Acid; Piperacillin; Pneumonia, Bacterial; Postoperative Complications; Prognosis; Prospective Studies; Tazobactam

2001
Piperacillin, beta-lactam inhibitor plus gentamicin as empirical therapy of a sequential regimen in febrile neutropenia of pediatric cancer patients.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2001, Volume: 9, Issue:5

    Topics: Adolescent; Anti-Bacterial Agents; Bacterial Infections; Child; Drug Therapy, Combination; Enzyme Inhibitors; Fever; Gentamicins; Germany; Humans; Neoplasms; Neutropenia; Penicillanic Acid; Penicillins; Piperacillin; Prospective Studies; Sulbactam; Tazobactam; Treatment Outcome

2001

Other Studies

4 other study(ies) available for tazobactam and Neoplasms

ArticleYear
Impact of antibiotic resistance on outcomes of neutropenic cancer patients with
    BMJ open, 2019, 05-24, Volume: 9, Issue:5

    Topics: Anti-Bacterial Agents; Bacteremia; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; International Cooperation; Logistic Models; Multicenter Studies as Topic; Neoplasms; Neutropenia; Observational Studies as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Research Design; Retrospective Studies; Tazobactam; Time Factors

2019
Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen.
    The Journal of antimicrobial chemotherapy, 2019, 10-01, Volume: 74, Issue:10

    Topics: Adolescent; Anti-Bacterial Agents; Bacterial Infections; Body Weight; Child; Child, Preschool; Female; Fever; Glomerular Filtration Rate; Humans; Infant; Male; Microbial Sensitivity Tests; Neoplasms; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam

2019
Generic piperacillin/tazobactam is not associated with galactomannan false-positivity in adult patients with cancer: a case-control study.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2015, Volume: 34, Issue:7

    Topics: Adult; Aged; Anti-Bacterial Agents; Antigens, Fungal; Aspergillosis; Case-Control Studies; False Positive Reactions; Female; Galactose; Humans; Male; Mannans; Middle Aged; Neoplasms; Penicillanic Acid; Piperacillin; Retrospective Studies; Tazobactam; Time Factors

2015
Control of glycopeptide-resistant enterococci in an oncology unit.
    Pharmacotherapy, 2000, Volume: 20, Issue:9 Pt 2

    Topics: Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Cohort Studies; Cross Infection; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Fever; Glycopeptides; Humans; Infection Control; Neoplasms; Neutropenia; Oncology Service, Hospital; Penicillanic Acid; Penicillins; Piperacillin; Prospective Studies; Tazobactam; Treatment Outcome

2000